文献速递血管炎

糖皮质激素治疗巨细胞动脉炎的复发率:一项Meta分析

Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2020-05-19

该系统评价纳入34项研究共2505例患者,评估单用糖皮质激素治疗的巨细胞动脉炎患者复发率。汇总复发率为47.2%(95%CI 40.0-54.3),异质性高(I2=93%)。复发率与发表年份和糖皮质激素疗程较短相关,而与初始剂量无关。

要点

  • 单用糖皮质激素的巨细胞动脉炎患者约半数复发,汇总复发率47.2%。
  • 初始剂量、有效治疗时长、随访时长、性别和年龄与复发率无关。

核心结论

  • 单用糖皮质激素的巨细胞动脉炎患者中,复发发生在约一半患者,且数十年来无改善。
  • 复发率更多与糖皮质激素给药疗程短相关,而非与诱导期初始剂量相关。
  • 结果支持临床试验设计应包含至少12个月的糖皮质激素治疗。

研究设计与样本

  • 系统评价和Meta分析,检索Medline至2017年12月。
  • 共纳入34项研究(2505例患者),包括8项随机对照试验(RCT)。
  • 采用随机效应模型汇总复发率。

主要发现

  • 总复发率为47.2%(95%CI 40.0-54.3),异质性高(I2=93%)。
  • RCT纳入患者的复发率显著高于观察性研究患者(P<0.0001),但按设计分组差异不显著(P=0.06)。
  • 复发率与较短糖皮质激素疗程相关(17项研究,每增加1个月疗程复发率降低1.7%;P<0.001)。
  • RCT中计划糖皮质激素疗程(12.8个月)短于观察性研究(28.8个月)。

关键数值与推荐

  • 总复发率47.2%(95%CI 40.0-54.3)。
  • 每增加1个月糖皮质激素疗程复发率降低1.7%(P<0.001)。
  • 有效糖皮质激素疗程(P=0.23)、初始剂量(P=0.49)、随访时长(P=0.14)、性别(P=0.29)和年龄(P=0.43)与复发率无关。

临床怎么用

  • 对于单用糖皮质激素的巨细胞动脉炎患者,应预期约半数可能复发。
  • 延长糖皮质激素疗程可能降低复发风险,而非仅提高初始剂量。
  • 临床试验设计应考虑至少12个月的糖皮质激素治疗。

局限性

  • 纳入研究间异质性高(I2=93%)。
  • 复发率定义和评估可能在各研究间存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The relapse rate of patients with giant cell arteritis (GCA) treated with glucocorticoids (GCs) alone varied widely in observational series and randomized controlled trials (RCTs). The purpose of this systematic review was to evaluate the prevalence of relapse and predisposing factors in patients receiving GCs alone. METHODS: We searched Medline up to December 2017. The prevalence of relapse was pooled using a random-effects model. RESULTS: A total of 34 studies (2,505 patients), comprising 8 RCTs, were included. The overall prevalence of relapse was 47.2% (95% confidence interval 40.0, 54.3) with a high heterogeneity (I2 = 93%). Prevalence of relapse was significantly higher for patients included in an RCT compared to those included in an observational study (P < 0.0001), but was not significantly different according to design (P = 0.06). The relapse rate was associated with year of publication (34 studies, rate increase of 8.3% for 1 decade; P < 0.0001) and with shorter GC regimens (17 studies, rate decrease of 1.7% for 1 additional month; P < 0.001), the duration of scheduled GC therapy being shorter in RCTs (12.8 months) compared to observational studies (28.8 months). The effective duration of GC therapy (P = 0.23), initial GC dose (P = 0.49), duration of follow-up (P = 0.14), sex (P = 0.29), and age (P = 0.43) were not associated with the prevalence of relapse. CONCLUSION: GCA relapses occur in half of patients and without improvement across decades in patients receiving GC alone, and the relapse rate is more related to short duration of GC administration than to the initial dose at induction. These results advocate for trial design with at least 12 months of GC therapy.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Mainbourg S, Addario A, Samson M, et al. Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis. Arthritis Care Res (Hoboken). 2020. PMID: 30951256. doi:10.1002/acr.23901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。